Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Marincola to lead Kite’s cell therapy research; plus moves at T-knife, Applied Molecular Transport, Frequency and NexImmune

January 20, 2021 2:32 AM UTC

Kite Pharma Inc. hired Francesco Marincola as SVP and global head of cell therapy research, effective Feb. 1. Marincola joined the Gilead Sciences Inc. (NASDAQ:GILD) unit from Refuge Biotechnologies Inc., where he was president and CSO. Marincola was also a tenured investigator at NIH in 1990-2013, and spent 15 of the 23 years as chief of the infectious disease and immunogenetics section at the NIH Clinical Center. 

T-knife GmbH hired Thomas Soloway as CEO and Camille Landis as CBO and CFO. Soloway succeeds founding CEO Elisa Kieback, who is now CTO at the company, which emerged from stealth in August with a transgenic mouse platform designed to generate human, high affinity TCRs to treat solid tumors. Soloway was EVP, COO at  Audentes Therapeutics Inc., which Astellas Pharma Inc. (Tokyo:4503) acquired for about $3 billion. Landis was SVP, corporate development at  Unity Biotechnology Inc. (NASDAQ:UBX). ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article